Decreased salivary lactoferrin levels are specific to Alzheimer's disease by González Sánchez, Marta et al.
EBioMedicine 57 (2020) 102834
Contents lists available at ScienceDirect
EBioMedicine
journal homepage: www.elsevier.com/locate/ebiomResearch paperDecreased salivary lactoferrin levels are specific to Alzheimer’s diseaseMarta Gonzalez-Sancheza,b, Fernando Bartolomea,*, Desiree Antequeraa,
Veronica Puertas-Martínc, Pilar Gonzalezc, Adolfo Gomez-Granded, Sara Llamas-Velascoa,b,
Alejandro Herrero-San Martína,b, David Perez-Martíneza,b, Alberto Villarejo-Galendea,b,
Mercedes Atienzae, Miriam Palomar-Bonete, Jose Luis Canteroe, George Perryf, Gorka Oriveg,
Borja Iba~nezh, Hector Buenoi, Valentin Fusterj, Eva Carroa,*
aNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de
Octubre Research Institute (imas12), 28041 Madrid, Spain
b Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain
c Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Hospital Universi-
tario 12 de Octubre Research Institute (imas12), Madrid, Spain
d Nuclear Medicine Service, Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid,
Spain
e Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Dis-
eases, Spain
f Department of Biology and Neurosciences Institute, University of Texas at San Antonio, San Antonio, TX, USA
g Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Center for Biomedical
Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
h Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; IIS-Fundacion
Jimenez Díaz Hospital, Madrid, Spain
i Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Facultad de
Medicina, Universidad Complutense de Madrid, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Cardiology Department, Hospital
Universitario 12 de Octubre, Madrid, Spain
j Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, United StatesA R T I C L E I N F O
Article History:
Received 16 April 2020
Revised 15 May 2020
Accepted 29 May 2020
Available online 22 June 2020* Corresponding authors.
E-mail addresses: fbartolome.imas12@h12o.es (F. Bar
(E. Carro).
https://doi.org/10.1016/j.ebiom.2020.102834
2352-3964/© 2020 The Authors. Published by Elsevier B.A B S T R A C T
Background: Evidences of infectious pathogens in Alzheimer’s disease (AD) brains may suggest a deteriorated
innate immune system in AD pathophysiology. We previously demonstrated reduced salivary lactoferrin (Lf)
levels, one of the major antimicrobial proteins, in AD patients.
Methods: To assess the clinical utility of salivary Lf for AD diagnosis, we examine the relationship between
salivary Lf and cerebral amyloid-b (Ab) load using amyloid-Positron-Emission Tomography (PET) neuroim-
aging, in two different cross-sectional cohorts including patients with different neurodegenerative disorders.
Findings: The diagnostic performance of salivary Lf in the cohort 1 had an area under the curve [AUC] of 095
(09110992) for the differentiation of the prodromal AD/AD group positive for amyloid-PET (PET+) versus
healthy group, and 097 (09241) versus the frontotemporal dementia (FTD) group. In the cohort 2, salivary
Lf had also an excellent diagnostic performance in the health control group versus prodromal AD compari-
son: AUC 093 (08760989). Salivary Lf detected prodromal AD and AD dementia distinguishing them
from FTD with over 87% sensitivity and 91% specificity.
Interpretation: Salivary Lf seems to have a very good diagnostic performance to detect AD. Our findings sup-
port the possible utility of salivary Lf as a new non-invasive and cost-effective AD biomarker.
Funding: Instituto de Salud Carlos III (FIS15/00780, FIS18/00118), FEDER, Comunidad de Madrid (S2017/BMD-
3700; NEUROMETAB-CM), and CIBERNED (PI2016/01) to E.C.; Spanish Ministry of Economy and Competitive-
ness (SAF2017-85310-R) to J.L.C., and (PSI2017-85311-P) to M.A.; International Centre on ageing CENIE-POC-
TEP (0348_CIE_6_E) to M.A.; Instituto de Salud Carlos III (PIE16/00021, PI17/01799), to H.B.
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Research in context
Evidence before this study
We searched PubMed for articles published in English up to
March 2020 with the terms “Alzheimer’s biomarkers”, “periph-
eral biomarkers”, “saliva proteins”, “saliva function”, “preclini-
cal Alzheimer”, “Alzheimer prediction”, “lactoferrin”,
“infections”, “immune system”, among others. All these studies
conclude the urgent need for the development of early diagnos-
tic methods that can accurately detect and diagnose Alzheim-
er's disease (AD). In recent years, there have been intensified
efforts in the search for minimum or non-invasive peripheral
markers, such as blood, or saliva, for the early diagnosis of AD.
Findings have shown the association between AD and immune
system, including virus, bacteria and yeast infections, which is
associated with an increased inflammatory response. Moreover,
it has been proposed that brain infections may be involved in
the development of AD. The dissemination of oral microorgan-
isms to the brain is controlled by antimicrobial peptides, as part
of the innate immune system. In the last decade, several studies
have explored the role of these antimicrobial peptides as poten-
tial biomarkers for AD. In 2017, we showed that salivary lacto-
ferrin (Lf) discriminates between patients with mild cognitive
impairment (MCI) and AD from control subjects.
Added value of this study
This is, to our knowledge, the first study to assess the excellent
diagnostic performance and specificity of a saliva-based single
biomarker to detect prodromal AD and AD dementia based on
their amyloid-PET biomarker profile. Moreover, an indepen-
dent cross-sectional independent study was able to replicate
the diagnostic performance of saliva Lf concentrations. The
results shown that salivary Lf levels are decreased in AD and
are associated with amyloid-PET imaging profile even in pro-
dromal disease. The fact that salivary Lf levels are unchanged in
other degenerative dementia, such as frontotemporal dementia
(FTD), supports the possible use of salivary Lf in the differential
diagnosis of AD vs other dementias.
Implications of all the available evidence
The most clinically relevant finding of this study is the excellent
diagnostic performance of salivary Lf to detect prodromal AD
and AD dementia distinguishing from other dementia as FTD,
with sensitivities and specificities over 87% and 91%, respec-
tively. Our results support the use of salivary Lf as an easily
accessible, non-invasive and cost-effective biomarker for early
AD diagnosis. Earlier and more reliable diagnoses for AD will
have a direct impact on the design of future clinical trials.
Finally, this study also propose that salivary Lf represents one
of the main/first defence line against pathogens, hence low Lf
levels in saliva may exacerbate AD risk.
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Alzheimer’s disease (AD) is one of the most devastating neurode-
generative disorders representing a major public health concern with
more than 30 million people affected worldwide. The cause of the
disease is still unknown but the most accepted hypothesis states that
amyloid-b (Ab) accumulation in the brain could initially trigger the
pathological cascade.
Accumulated evidence suggests that bacterial and viral infections
may be implicated in AD pathogenesis [15]. In the cascade of eventspreceding AD, oral and gastrointestinal microorganisms may play a
role [6,7], and different types of microbes have shown to stimulate
Ab aggregation and deposition [8,9]. Therefore, it may exist an inter-
play between genetic and environmental risk factors including toxins
and/or bacterial, viral and fungal pathogens in the sporadic form of
late-onset AD reflecting its complex and multifactorial aetiology [10].
The question of whether oral infections could be considered as a
risk factor for AD has generated considerable research in recent years.
Antimicrobial proteins and peptides (APPs), also called host defence
agents, are the primary effector molecules of innate immunity. A
novel role for APPs has been proposed in AD pathology. The emerging
role of microbes and innate immune pathways in AD pathology also
suggests that APPs may be considered for early therapeutic interven-
tions in future clinical trials. Pathogen-targeting agents and brain
infections markers are involved in amyloid aggregation, reinforcing
the possible relationship between AD and brain infections [11,12].
Biomarkers reflecting innate immune system integrity could
therefore be useful for both, accurate and early diagnosis, as well as
disease prognosis. A promising biomarker candidate is lactoferrin
(Lf), an iron-binding protein belonging to the transferrin family and
expressed in all body fluids, particularly in exocrine fluids, tears or
saliva [13]. Lf has a wide variety of physiological functions including,
antioxidant activities, neuroprotective properties, regulation of the
immune response, anti-inflammatory and anti-carcinogenic potential
[1418]. In addition, Lf has been previously detected in senile pla-
ques, neurofibrillary tangles [19] and microglia from AD brains [20].
Since Lf is one of the major antimicrobial peptides in saliva, it further
represents an important defensive element by inducing a broad-
spectrum of antimicrobial effects against bacteria, fungi, protozoa,
viruses and yeasts [21]. The antimicrobial effects of Lf are conferred
by its highly positive charged N-terminal region [22]. These functions
are maintained by its hydrolysis products, a number of Lf-derived
peptides that by retaining the cationic N-terminal region of the native
protein also retain many of the Lf activities and in some cases, they
can be even more potent than the parent protein [21,23].
We have previously shown decreased Lf levels in saliva samples
from mild cognitive impairment (MCI) and AD patients compared
with normal elderly subjects [24]. In the present study, we have eval-
uated the diagnostic utility of salivary Lf in a well-characterised
cohort of AD and frontotemporal dementia (FTD) patients, as well as
in normal elderly subjects. Results have been lately validated in an
independent cohort of MCI patients and healthy controls. In order to
assess the salivary Lf specificity and its relationship with the patho-
physiological process of AD, only participants with known amyloid-
Positron-Emission Tomography (PET) status were included.
2. Materials and methods
2.1. Human donors
Two prospective, cross-sectional, multicenter studies were exam-
ined divided in two different cohorts. Study participants from cohort
1 were consecutively enrolled between 2014 and 2018 from the 12
de Octubre University Hospital Neurology Service in Madrid (Spain)
and Pablo de Olavide University in Sevilla (Spain). Study participants
from cohort 2 were consecutively enrolled between June 2017 and
December 2018 as part of the Atherobrain - Heart to Head (H2H)
project. Data from both cohorts were analysed in 2018.
All participants were classified using established diagnostic crite-
ria into those with MCI or dementia including AD [25-27] and FTD
[28], and those without clinical signs of cognitive impairment classi-
fied as healthy controls. Diagnosis was based on detailed clinical
assessment, neuropsychological study, neuroimaging and amyloid-
Positron-Emission Tomography (PET) scan results. Global cognition
was assessed using the Mini Mental State Examination (MMSE) [29].
Functional impairment was measured via the Clinical Dementia
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Exclusion criteria were evidences of concomitant psychiatric, neuro-
logical or non-neurological medical conditions or medications that
could affect cognition. Inclusion criteria for controls were age over
60, MMSE score over 27, no history or clinical signs of neurological or
psychiatric disease, and preservation of social and functional abilities.
116 participants composed cohort 1: 52 out of 116 were healthy
asymptomatic subjects considered as controls, 21 out of 116 were
diagnosed as MCI due to AD, 25 out of 116 were AD dementia and 18
out of 116 were FTD. 142 participants composed cohort 2: 74 out of
142 were cognitively normal subjects, and 68 out of 142 patients
were clinically diagnosed as MCI. From the MCI group, 39 subjects
were diagnosed as prodromal AD and the others as MCI not due to
AD. Of all control participants 4 subjects from cohort 1 and 4 subjects
from cohort 2 had a positive amyloid-PET (PET+) result. These partici-
pants were included in the demographic description to show the
population heterogeneity, but not in the statistical analysis due to the
small number of cases.
Approval of the study was obtained from the Research Ethics
Committee of each entity, and all participants provided written con-
sent to take part.
2.2. Saliva samples
Saliva samples were collected and processed from all subjects as
described previously [24]. Briefly, an unstimulated saliva sample
(about 051ml) was obtained by collection into a 2% sodium azide
solution pre-coated sterile plastic tube. Samples were collected at a
consistent time of day to avoid circadian effects and were kept on ice
during and following collection. After collection was completed,
saliva samples were pre-cleared by a low spin at 600£ g for 10min
at 4 °C. 05ml aliquots were stored at 80 °C after treatment with
Protease Inhibitor Cocktail (Roche).
2.3. DNA purification and APOE genotyping
Genomic DNA was extracted from peripheral blood using QIAmp
DNA Blood Mini Kit (Qiagen), according to the manufacturer instruc-
tions. Human APOE C112R and R158C polymorphisms were detected
to identify the APOE e2, e3 and e4 alleles, using LightCycler 480 II
Instruments Kit (Roche Diagnostics) following manufacturer instruc-
tions.
2.4. ELISA
Levels of Lf in saliva samples were determined using the Lf human
ELISA kit (ab200015, Abcam) according to manufacturer’s instruc-
tions.
2.5. Amyloid-PET scan
Amyloid-PET scan was carried out in all participants. [18F]-florbe-
tapir (Amyvid, Eli Lilly & Co. and Avid Radiopharmaceuticals Inc.),
[18F]-florbetaben (Neuraceq, Pyramidal Imaging Limited), and [18F]-
flutemetamol (Vizamyl, GE Healthcare) PET scans were performed at
the 12 de Octubre University Hospital, Pablo de Olavide University
and the National Centre for Cardiovascular Research (CNIC), as previ-
ously described [3133]. Images were generated 90110min after
[18F]florbetaben intravenous injection (mean dose, 300 MBq) or
90min after [18F]-flutemetamol intravenous injection (mean dose,
185 MBq; 20 min acquisition) or [18F]-florbetapir intravenous injec-
tion (mean dose, 370 MBq; 20 min acquisition). Images were ana-
lysed with the Syngo PET 672 (Siemens Healthcare) software and
IntelliSpace Portal (Philips Healthcare) software. PET scans were ana-
lysed using standardised criteria [34].2.6. Statistical analysis
We compared salivary Lf levels between the different diagnostic
groups according to the amyloid-PET imaging biomarker profile.
Numerical data are shown as mean § standard deviation (SD) and
categorical data as a percentage. To compare demographic, clinical,
and salivary Lf data within cohorts, we used one-way ANOVA fol-
lowed by Bonferroni correction or the nonparametric Kruskal-Wallis
rank test and non-parametric pairwise comparisons followed by Bon-
ferroni correction, according to sample distribution. Student’s t-test
was used for single pairwise comparisons. Fisher’s exact test was
used to compare the distribution of categorical data across groups.
Correlations between biomarker and subject’s features were assessed
using Spearman rank correlation. In addition, receiver operating
characteristic (ROC) curve using binomial logistic regression analysis
in the discovery cohort 1 and the validation cohort 2 were used to
determine the diagnostic accuracy of salivary Lf to differentiate
between diagnostic groups and amyloid-PET status. The optimal cut-
off point was determined by Youden’s J index (J = sensitivity + speci-
ficity  1) by analysing the cohort 1. Sensitivity, specificity and area
under the curve (AUC) were calculated in all cases. Statistical signifi-
cance was set at p < 005. Statistical analysis was performed using
GraphPad Prism version 600 and STATA/IC 142 for Windows.
3. Results
3.1. Demographics
Demographic and clinical data of participants are shown in Table 1
(cohort 1) and Table 2 (cohort 2). In cohort 1 (Table 1, n = 116 sub-
jects), 50 out of 116 participants were positive for amyloidPET
(PET+) (431% prevalence) and 66 out of 116 were negative (PET;
56% prevalence). From the PET+ group, 21 out of 50 were clinically
diagnosed with MCI due to AD (MCI-PET+; 42% prevalence), and 25
out of 50 were diagnosed with AD dementia (AD-PET+; 50% preva-
lence). Four controls showed a PET+ status (Control-PET+), represent-
ing the 77% of all controls in cohort 1. About the PET subjects, 18
out of 66 were clinically diagnosed with FTD (FTD-PET; 273% prev-
alence) and 48 out of 66 were found asymptomatic (Control-PET;
727% prevalence).
In the independent validation cohort (cohort 2; Table 2, n = 142
subjects), 43 out of 142 participants were PET+ (303% prevalence) and
99 out of 142 were PET; 739% prevalence). All PET+ subjects received
the diagnosis of MCI due to AD except for 4 participants, which stayed
cognitively healthy. This group represented the 54% of all controls in
cohort 2. From the PET group, 29 out of 99 were diagnosed with MCI
probably not due to AD (MCI-PET; 293% prevalence) and 70 out of
99 were found asymptomatic (707% prevalence).
No significant sex differences were found between groups. Mean
age was statistically similar in all groups except for the FTD group
from cohort 1, which was higher (Table 1). All patients showed lower
MMSE scores than controls, specially AD and FTD groups. As
expected, APOE e4 genotype was significantly higher in MCI-PET+
group and AD compared with asymptomatic subjects and FTD
patients, according to previous publications [35-36].
In cohort 2, mean age was statistically similar in all groups. MCI
patients showed lower MMSE scores than controls. Prevalence of
APOE e4 genotype was significantly higher in MCI-PET+ group and AD
compared with asymptomatic subjects.
MCI-PET group also showed a significantly higher prevalence of
APOE e4 genotype compared with the healthy control group.
3.2. Salivary LF levels across diagnostic groups
In cohort 1, salivary Lf levels were significantly lower in MCI-PET+
(38§ 2mg/ml) and AD (36§ 15mg/ml) groups compared with
Table 1
Demographic and clinical data of the participants in cohort 1.
Cohort 1
Characteristic Control-PET Control-PET+ MCI-PET+ AD-PET+ FTD-PET p-value
(n = 48) (n = 4) (n = 21) (n = 25) (n = 18) #
Age, mean (SD), y 669 (59) 759 (36) 688 (75) 672 (92) 738 (56)a,b <001
Female sex, n (%) 33 (688) 2 (500) 8 (381) 12 (480) 11 (611) ns
Disease duration, mean (SD), y   28 (15) 40 (17) 37 (17) ns
MMSE score, mean (SD) 290 (11) 280 (08) 251 (23)d 192 (60)c,d 205 (92)d <00001
CDR, mean (SD) 0 0 05 13 (0·5) 09 (07) NA
APOE e4 carrier, No. (%) 6 (171)a,c  14 (667) 12 (480) 1 (56)c,e <00001
Saliva Lf,mg/ml (SD) 77 (24) 98 (54) 38 (20)d,g 36 (15)d,g 97 (29)f <00001
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease dementia; FTD, frontotemporal dementia; PET+, positive
amyloid PET scan; PET, negative amyloid PET scan; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; Lf, Lacto-
ferrin; NA, not applicable; ns, non-significant. #p value indicates statistical difference within the cohort1
[Bonferroni:
a p < 005 vs. AD-PET+.
b p < 001 vs. Control-PET.
c p < 00001 vs. MCI-PET+.
d p < 00001 vs. Control-PET.
e p < 001 vs. AD-PET+.
f p < 005 vs. Control-PET.
g p < 00001 vs. FTD-PET].
Note: Control-PET+ group is not included in statistical analysis.
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Bonferroni; Fig. 1a), and FTD patients (mean 97§ 29mg/ml; p <
00001, Bonferroni; Fig. 1a). Lf levels in FTD group were slightly
increased compared with controls (p < 005, Bonferroni) but the dif-
ference was much more relevant when comparing with MCI-PET+
and AD-PET+groups. No significant differences in salivary Lf levels
were found between MCI-PET+ and AD patients (Table 1, Fig. 1a).
Regarding the control-PET+ group, levels of Lf were inconsistent,
showing values of 160, 126, 60 and 46mg/ml.
In cohort 2, saliva Lf levels were significantly lower in MCI-PET+
(35§ 25mg/ml) group compared with healthy controls
(92§ 29mg/ml; p < 00001, Bonferroni), and MCI-PET (mean
74§ 46mg/ml; p < 00001, Bonferroni; Table 2, Fig. 1b). No differ-
ences in salivary Lf levels were found between control and MCI-PET
groups. Regarding the control-PET+ group, levels of Lf tended to be
down-regulated, and the 4 subjects showed values of 65, 44, 38
and 37mg/ml.
Cohort 1 and cohort 2 combination (n = 250, excluding the 8 con-
trol-PET+ subjects), resulted in 165 out of 250 PET and 85 out of 250
PET+ subjects. Salivary Lf levels were significantly higher in the PETTable 2
Demographic and clinical data of the participants in cohort 2
Cohort 2
Characteristic Control-PET Contr
(n = 70) (n = 4
Age, mean (SD), y 711 (57) 703
Female sex, n (%) 43 (623) 2 (50
Disease duration, mean (SD), y  
MMSE score, mean (SD) 286 (11) 295
CDR, mean (SD) 0 0
APOE e4 carrier, No. (%) 4 (57) 0
Saliva Lf,mg/ml (SD) 92 (29)d 46 (1
Abbreviations: MCI, mild cognitive impairment; PET+, positi
MMSE, Mini-Mental State Examination; CDR, Clinical Demen
significant. #P value indicates statistical difference within th
[Bonferroni:
a p < 005 vs. Control-PET.
b p < 001 vs. Control-PET.
c p < 00001 vs. Control-PET-.
d p < 00001 vs. MCI-PET+].
Note: Control-PET+group is not included in statistical analysigroup (85§ 32mg/ml) compared with the PET+ group
(36§ 21mg/ml; p < 00001, Student’t; Fig. 1c). By excluding the
control group, analysis also reported significant differences in sali-
vary Lf levels between PET, covering FTD and some MCI patients
(83§ 42mg/ml), and PET+patients (p < 00001, Student’t; Fig. 1d).3.3. Correlations between salivary LF and demographic, clinical, and
APOE genotype
We then investigated correlations between salivary Lf concentra-
tions and clinical and demographic data, including age, MMSE score,
disease duration and CDR, in separated groups within cohorts and by
combinination of all of them. We also assessed the effects of APOE e4
genotype in Lf levels. We found that higher salivary Lf levels were
associated with higher MMSE scores (r = 069; p < 001) and lower
CDR scores (r =059; p < 001) in the FTD group (Table 3). No cor-
relations were found either with MMSE or CDR in the other groups in
cohort 1 and 2, nor between salivary Lf levels and age or disease
duration in the combined or in the separated groups..
ol-PET+ MCI-PET MCI-PET+ p-value
) (n = 29) (n = 39) #
(45) 753 (59) 744 (53) ns
0) 20 (690) 26 (667) ns
26 (17) 33 (18) ns
(06) 251 (22)c 243 (21)c < 00001
0·5 0·5 NA
7 (241)a 12 (308)b < 0001
3) 74 (46)d 35 (25) < 00001
ve amyloid PET scan; PET, negative amyloid PET scan;
tia Rating; Lf, Lactoferrin; NA, not applicable; ns, non-
e cohort 2.
s.
Fig. 1. Salivary Lf levels by clinical diagnosis and amyloid-PET biomarker profile. Box and whisker plots showing salivary Lf levels across diagnostic groups within (a) cohort 1,
and (b) cohort 2. Boxes represent the 25th, 50th and 75th data percentiles. Whiskers represent the lowest and highest data. Scatter plots showing salivary Lf levels in (c) all subjects
grouped as negative (n = 165) and positive (n = 85) amyloid-PET biomarker profile (excluding the control-PET+ subjects), and (d) in patients (excluding healthy asymptomatic con-
trols) grouped as negative (n = 47) and positive (n = 85) amyloid-PET biomarker profile. Differences between groups were assessed using Kruskal-Wallis test or one-way ANOVA fol-
lowed by Bonferroni and Student’s t-test. *p < 005; ****p < 00001. Lf, lactoferrin; MCI, Mild cognitive impairment; AD, Alzheimers disease dementia; FTD, frontotemporal
dementia; PET+, positive amyloid-PET scan; PET, negative amyloid-PET scan.
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Lf levels in saliva in APOE e4 carriers compared with APOE e2 and e3
carriers within the diagnostic groups, suggesting that the APOE e4
genotype is not related to salivary Lf levels.
3.4. Diagnostic value for LF
Lf results were analysed using logistic regression models in cohort
1 and the validation cohort 2, excluding control PET from both
cohorts. Using the Youden’s index, we found that the optimal cut-off
point to differentiate salivary Lf from MCI/AD-PET+patients and con-
trol-PET group was 563mg/ml in cohort 1. At this cut-off point,
specificity and sensitivity were estimated in 9167% and 8696%,
respectively. The obtained area under the curve (AUC) was 0952(95% CI, 0911 - 0992) (Table 4, Fig. 2a). Using the same cut-off
point, the obtained sensitivity and specificity differentiating MCI/AD-
PET+ from FTD-PET patients were 8696% and 8889%, respectively.
The AUC was 097 (95% CI, 0924 - 100) (Table 4, Fig. 2b). Combin-
ing Lf levels from all subjects in cohort 1 grouped as PET and PET+
and keeping the cut-off point of 563mg/ml, we obtained 8696%
sensitivity and 9091% specificity (Table 4, Fig. 2c).
In the validation cohort 2 analyses, the cut-off estimated from
cohort 1 was replicated. The AUC to differentiate MCI-PET+ patients
from control-PET was 093 (95% CI, 0876 - 0989), with 9286%
specificity and 8705% sensitivity (Table 4, Fig. 2d). Both, the accuracy
and specificity to differentiate MCI-PET+ from MCI-PET groups were
lower (Table 4, Fig. 2e), due to the higher variability in the salivary Lf
levels observed in the MCI-PET group. That could be explained
Table 4
Sensibility and specificity of salivary Lf in cohort 1 and validation cohort 2.
Cohort 1 Validation cohort 2
(n = 112) (n = 138)
MCI/AD-PET+ MCI/AD-PET+ MCI/AD-PET+ MCI-PET+ MCI-PET+ MCI-PET+
vs. Control vs. FTD-PET vs. PET vs. Control vs. MCI-PET vs. PET
AUC 095 097 096 093 076 088
(95% CI) (0911, 0992) (0924, 1) (0922, 0990) (0876, 0989) (0637, 0878) (0817, 0945)
Sensitivity,% 8696 8696 8696 8705 8462 8205
Specificity,% 9167 8889 9091 9286 5862 8283
Accuracy,% 8936 8750 8929 88 099 7353 8261
Cut-off,mg/ml 563 563 563 563 563 563
Performance of salivary Lf analysed by receiver operating characteristic (ROC) curve, corresponding to the discovery data set (cohort
1, left) and the validation data set (cohort 2, right). The optimal cut-off point to differentiate patients with AD from healthy controls
from the cohort 1 was used to calculate sensibilities and specificities against the other groups analysed. This optimal cut-off point
was determined by the Youden’s index. Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease dementia; FTD,
frontotemporal dementia; PET+, positive amyloid PET scan; PET, negative amyloid PET scan; AUC: area under the ROC curve; Lf,
Lactoferrin.
Table 3




Whole dataset Control MCI/AD FTD
MMSE 042a 004 003 069b
CDR 049a  019 059b
Cohort 2
Correlation coefficient
Whole dataset Control MCI-PET+ MCI-PET
MMSE 040a 020 027 004
CDR 053a   
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease dementia; FTD, frontotempo-
ral dementia; PET+, positive amyloid PET scan; PET-, negative amyloid PET scan; MMSE, Mini-Mental
State Examination; CDR, Clinical Dementia Rating.
[Spearman:
a p < 00001.
b p < 001].
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geneous group with different and/or mixed non-amyloid aetiologies.
Combining Lf levels from all subjects in cohort 2 grouped as PET and
MCI-PET+ and keeping the cut-off point of 563mg/ml from cohort 1,
we obtained 82.05% sensitivity and 8283% specificity with an AUC of
088 (95% CI, 0817 - 0945) (Table 4, Fig. 2f). Overall, these results
revealed that salivary Lf is able to differentiate between subjects with
positive and negative cerebral amyloidosis with high accuracy.
4. Discussion
Here we show that reduced salivary Lf levels seem to be specific to
AD as such observation is not extended to healthy elderly controls or
FTD, as example of different dementia, neither to advanced age
healthy controls. We demonstrate that reduced Lf levels are associ-
ated to positive amyloid PET result, one of the available pathophysio-
logical validated AD biomarkers. These findings agree with our
previously reported study in which reduced salivary Lf levels were
found in amnesic MCI and AD patients [24].
Brain Ab aggregation is thought to play a major role in AD aetiol-
ogy, but the amyloid cascade hypothesis cannot explain the patho-
logical process of AD by itself. In 2016, a hypothesis postulated that
brain infections might play an initial role in amyloid plaque forma-
tion and the development of AD [37], proposing a potential novel
role for APPs in AD pathophysiology [11]. These infections lead to
persistent inflammatory stimuli altering the immune response [38].
Different lines of evidence suggest that AD-affected brains host virus,
including herpes virus and hepatitis virus [1-5], and bacteria, includ-
ing Chlamydia, Borrelia spirochetes, or Helicobacter Pylori [39]. Thosebacterial and viral populations in the brain might induce Ab aggrega-
tion, triggering the AD pathophysiological process [1-5, 8, 9]. How-
ever, it remains unclear whether the entry of pathogens occurred at
the onset of AD or it may be the consequence of a leaky blood brain
barrier (BBB) induced by chronic infections-derived inflammatory
processes or, ultimately, if it is secondary to AD itself. It is important
to recognise that infections can occur decades before evident signs of
dementia. In agreement with this hypothesis, a number of risk fac-
tors, including chronic infections, obesity, diabetes, depression and
stress among others, are known to contribute down-regulating the
innate immune system and thus increasing the risk for infections. On
this regard, is interesting to mention the recent work carried out by
Ilievski and colleagues in which they have found a connection
between oral infection and the development of AD-like pathology
[40]. The authors orally administered Porphyromonas gingivalis (Pg)
and/or its product gingipain to 8-month-old C57/BL6 mice for
22 weeks. Then, they found hippocampal and cortical neuropathol-
ogy including Ab plaques, neurofibrillary tangle formation, astroglio-
sis and microgliosis in the treated mice, but not in the control
group [40]. More recently, Dominy and colleagues demonstrated
the presence of Pg DNA and gingipain antigens in brains from AD
patients [41].
Oral homoeostasis is dependant upon saliva and its protein con-
tent. An alternative approach to understand the AD aetiopathogene-
sis has been recently reported: a potential microbial infection and
innate immune origins for the disease [42]. This approach opened the
way for a paradigm shift in studying a new “infection hypothesis,” or
perhaps more broadly, “innate immune system dysregulation
hypothesis”. It suggests the role of chronic infections in the
Fig. 2. Receiver operating characteristic (ROC) analysis of salivary Lf in cohort 1 and cohort 2. ROC curves and their corresponding areas under the curve (AUCs) to differentiate
between (a) MCI/AD-PET+ patients and control-PET, (b) MCI/AD-PET+ and MCI/FTD-PET patients, and (c) MCI/AD-PET+ and PET in cohort 1. ROC curves and their corresponding
areas under the curve (AUCs) to differentiate between (d) MCI-PET+ patients and control-PET, (e) MCI-PET+ and MCI-PET patients, and (f) MCI-PET+ and PET in cohort 2. ROC;
receiver operating characteristic; MCI, mild cognitive impairment; AD, Alzheimer’s disease dementia; FTD, frontotemporal dementia; PET+, positive amyloid-PET scan; PET, nega-
tive amyloid-PET scan.
M. Gonzalez-Sanchez et al. / EBioMedicine 57 (2020) 102834 7development of AD, as well as a potential deregulation of the human
innate immune response to these infections, as a plausible route for
new investigations of the aetiology and pathophysiology of AD [43].
Although AD is a complex disease and microbial infection may not be
the sole cause, this new paradigm may provide novel targets for the
prevention and treatment of this devastating disease.
The dissemination of oral microorganisms in the brain is con-
trolled by APPs, as part of the innate immune system. In the last
decade, several studies have explored the role of these APPs as poten-
tial biomarkers for AD [11]. In 2017, we showed that salivary Lf levels,
one of the major antimicrobial proteins in saliva, discriminates
between patients with MCI and AD and control subjects [24].
Although Lf cleavage generates antimicrobial peptides, sometimes
with higher antimicrobial capacity, the protein itself has antimicro-
bial effects as these properties are conferred by its highly positive
charged N-terminal domain and this domain is retained by its gener-
ated peptides. These differences come from the observation of Lf-
derived peptides exerted higher antibacterial capacity compared to
native Lf. However, that was not the case of the antiviral capacity as
several works demonstrated that mature protein has much more
effect [21]. APPs are defensive agents constitutively expressed, but
they can be modulated during inflammation or a microbial challenge,
including chronic bacterial or viral infections. APPs have been studied
for decades for their action against pathogens, and theirimmunostimulatory effects [23]. As part of the innate immune sys-
tem, APPs are defensive peptides that enter the brain and efficiently
target pathogens through synergistic pathways [11]. The normal pro-
duction of APPs may be reduced because of a number of factors such
as a weakened immune system or damaged defence cells. We then
hypothesise that reduced levels of salivary Lf could reflect compro-
mised immunity resulting in an enhanced risk of brain infections. Lf
is known to be transferred from the sublingual mucosa to the brain
[44]. In this context, favourable Lf effects on brain are expected, and
they could be related to its antimicrobial capacity but also they may
stimulate the non-amyloidogenic processing of APP and the a-secre-
tase catalytic activity and expression in a mouse model of AD [45].
Human Lf exerts multifunctional effects displaying extensive anti-
microbial, anti-inflammatory and immunomodulatory activities. Lf
may deprive microorganisms such as bacteria, yeasts and parasites
binding and sequestering iron, which is essential for their growth
[46]. Lf has different iron binding statuses: the iron-free (apo) form,
the native form, and the iron-saturated (holo) form. It has been
shown that both, the apo-Lf form as well as the holo-Lf form mediate
agglutination of microorganisms indicating that Lf possess strong
iron-binding independent bacteriolytic properties [47]. Moreover,
previous studies also demonstrated that Lf showed antioxidant
effects depending on its iron binding status [48]. Oxidative stress or
damage such as protein oxidation, lipid oxidation, DNA oxidation,
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[49]. The antioxidant effect of Lf could be explained as Lf restrains
membrane lipid peroxidation by scavenging free iron radicals. These
iron radicals are cytotoxic activators of lipid peroxidation and oxida-
tive stress. It has been shown that Lf simultaneously enhances antiox-
idant activity by reducing ROS and enhancing SOD1 and reducing
inflammatory markers in AD mice [45]. In a recent study with AD
patients, Lf treatment showed significant improvements in antioxi-
dant and anti-inflammatory markers in serum, and reduced Ab42
and phosphorylated tau levels, as well as improved cognitive func-
tion [50]. Lf antioxidant activities have also been described in PD
experimental models in which this protein was able to prevent oxi-
dative stress and to upregulate the expression of antioxidant
enzymes. Simultaneously, the expression of glial markers and proin-
flammatory cytokines were found reduced [51-52]. Therefore, a
boosting effect of Lf may be potentially observed when this protein
exerts its antioxidant properties through its iron scavenging abilities
and this effect would potentiate the immune response [53].
In the present study, we report that salivary Lf levels are signifi-
cantly reduced in AD patients but not in patients with other dementia
such as FTD, suggesting a specific Ab-related link. To our knowledge,
this is the first study at examining the relationship between salivary
Lf and brain Ab plaques measured in vivo by amyloid-PET neuroim-
aging. Amyloid-PET has emerged as a tool for the diagnostic accuracy
of prodromal AD, as amyloid deposition occurs years before symp-
toms onset. MCI encompasses a heterogeneous syndrome with
several aetiologies including neurodegenerative diseases, vascular,
metabolic or psychiatric illness [27, 54]. Inaccuracy of clinicopatho-
logical correlation and common coexistence of different pathophysio-
logical processes make difficult in most cases to establish a suitable
diagnosis [27]. Furthermore, MCI without evidence of AD pathophysi-
ology continues to be a mixed and frequently poorly defined group.
In our study, Lf showed high variability levels in this group of
patients, likely reflecting their biological diversity.
We show that the presence of a positive amyloid-PET signal, that
indicates high amyloid plaque load, is highly associated with reduced
levels of salivary Lf. These findings support the hypothesis that AD
pathophysiology may be related to salivary levels of Lf and the innate
immune response to brain infections. Innate immune pathways are
commonly activated in other neurodegenerative disorders [55-58].
Therefore, it is remarkable that salivary Lf levels will not decrease in
other dementia such as FTD. A possible explanation could be that the
hypothalamic region, that controls body innate immunity, [59] is
affected in AD [60-63], but not in FTD. In addition to amyloid plaques
and neurofibrillary tangles, functional studies suggest that hypotha-
lamic dysfunction is a common event in AD, often early in the course
of disease [61]. Although there are evidences indicating that certain
hypothalamic regions are also affected in FTD, specifically those that
correlate with abnormal eating behaviours [64], they are different to
those affected in AD. The apparently AD-specific salivary Lf reduction
may thus not only be useful in the differential diagnosis but could
also provide important insights into selective immune vulnerability
in neurodegenerative diseases. The secretion of salivary proteins is
controlled by cholinergic parasympathetic nerves that release acetyl-
choline, evoking the secretion of saliva by acinar cells in the salivary
gland [65]. These parasympathetic nerves are connected with the
hypothalamus [6063]. We propose that early hypothalamic Ab
accumulation may disrupt hypothalamic function affecting salivary
gland regulation that ultimately results in reduced salivary Lf secre-
tion.
In 2011, the NIA-AA guidelines proposed a framework for the use
of imaging and CSF biomarkers in the preclinical, MCI and dementia
stages of AD [25,26,66,67]. However, these current biomarkers used
in AD research are expensive or invasive, making difficult or impossi-
ble to include them in the routine clinical use in non-specialised
health settings. Thus, the present research framework concludes theurgent need for the development of early diagnostic methods, incor-
porating new biomarkers that can accurately detect and diagnose AD.
In recent years, there have been intensified efforts in searching mini-
mum or non-invasive peripheral biomarkers in blood or saliva, for
the early diagnosis of AD. Our present work show that salivary Lf lev-
els are decreased in AD and are associated with amyloid-PET imaging
profile even in prodromal disease, assuming the multifactorial and
heterogeneous aetiology of dementia. The good correlation found in
our study between amyloid-PET status and saliva Lf levels suggest
that this inexpensive and easy-to-access measurement could be a
potential candidate-screening tool in patients with cognitive
impairment or suspicion of AD dementia.
In this study, we analysed Lf levels in cohort 1 where patients and
control subjects were recruited from regions in Central and South of
Spain. Second, the analysis was validated using the cohort 2 com-
posed of donors recruited from Central Spanish region. Our present
data demonstrates that the accuracy of salivary Lf as AD biomarker
remains in these two separated geographic areas, suggesting that sal-
ivary Lf levels can be considered as reproducible biomarker and they
may not be affected by other possible influences, including lifestyle
and exposure to environmental factors. Other works showed on the
contrary, that salivary Lf concentrations might be affected by circa-
dian rhythms and physical activity [68-70], or environmental and
lifestyle factors, including habits like smoking and medication-intake
[71-73]. Therefore, it will be important to replicate these findings in
larger-scale prospective and longitudinal studies with other different
cohorts even with much more geographic separation. This will allow
to accurately analysing the influence of other potential confounding
variables.
In conclusion, to our knowledge, this is the first study that
assesses the diagnostic performance and specificity of a salivary-
based single biomarker to detect prodromal AD and AD dementia
based on their amyloid-PET biomarker profile. Importantly, our find-
ings have been replicated in an independent cross-sectional study
able to replicate the diagnostic performance of saliva Lf concentra-
tion. Finally, this study also proposes that salivary Lf represents one
of the main/first lines of defence against pathogens, and that low Lf
levels in saliva may represent a reduced protection exacerbating the
risk of AD.
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